

BcV-mCov Stage III - Internal Report


The present internal report shows results of the Stage III tests for the Covid-19 vaccine named *BcV-mCov* (non-replicating viral vector):

Population A

- 87% successful inoculations
- 3% adverse effects

Spike-specific antibodies at day 28;

neutralizing antibodies after a booster dose at day 56. Adverse effects: pain at the injection site, headache in 3% of participants; paracetamol allowed for some participants to increase tolerability.



Population B

- 32% successful inoculations, 60% negative side effects

Small spike-specific antibodies at day 25; no antibodies after booster dose at day 45.

Adverse effects: pain at the injection site, headache, fever, chills, muscle ache, malaise in more than 60% of participants.

Population C

- 25% successful inoculations, 71% negative side effects

Small spike-specific antibodies at day 25; no antibodies after booster dose at day 46.

Adverse effects: pain at the injection site, headache, fever, chills, muscle ache, malaise in more than 71% of participants.

Population D

- 27% successful inoculations, 67% negative side effects

Small spike-specific antibodies at day 30; no antibodies after booster dose at day 51.

Adverse effects: pain at the injection site, headache, fever, chills, muscle ache, malaise in more than 67% of participants.

Technical advice: unsuccessful results in 3 out of 4 populations, with significant adverse effects and reduced generation of antibodies from both the initial inoculation and booster doses. Current state of vaccine not yet suitable for commercial deployment.

Technical Director, Penelope Pearson (PhD)

